Biological products

Biological products

Breakthrough in HIV/AIDS Treatment: Long-Term Delivery of Broadly Neutralizing Antibodies Using AAV Vector Shows Promise

Researchers from the University of Miami have made significant progress in the development of a new approach for preventing and treating HIV infection. The study, published in Nature Communications, presented a promising method of using adeno-associated virus (AAV) vector to deliver broadly neutralizing antibodies (bnAbs) for long-term HIV prevention and

Antineoplastic agents

ADC Treatment Rates Increase 3.7-Fold with Faster Access, Yet Older Women Face Inequitable Access Barriers

A new analysis conducted by Komodo Health and the Tigerlily Foundation, a national breast cancer patient advocacy organization, reveals significant progress in the adoption of antibody-drug conjugate (ADC) treatment in metastatic breast cancer. The study confirms growing clinical acceptance of this innovative therapy but also highlights persistent inequities in access

Biological products

Valink Therapeutics Secures $11.8 Million Funding to Advance Novel Therapeutics for Cancer Treatment

Valink Therapeutics Inc. has closed a significant funding round to accelerate the development of its novel therapeutics for improving cancer treatment outcomes. The company's proprietary bispecific antibody-drug conjugates (bsADCs) technology aims to address key limitations of current ADCs by integrating novel targeting strategies with improved payload delivery. The

Biological products

Alphamab Oncology Presents Promising Efficacy Data for JSKN003 in Phase I and Phase II Clinical Trials

JSKN003, a biparatopic anti-HER2 antibody-drug conjugate, has demonstrated promising efficacy in treating primary platinum-refractory ovarian cancer, HER2-positive metastatic colorectal cancer, and platinum-resistant ovarian cancer, according to data presented at the 2025 European Society for Medical Oncology Congress. The therapy showed a significant response rate, disease control rate, and overall survival

Azo compounds

Photoresponsive DNA Nanotechnology Holds Promise for Dynamic Biomaterials and Therapeutic Tools

Researchers have made significant progress in developing photoresponsive DNA nanotechnology, which has the potential to create dynamic biomaterials and therapeutic tools. This breakthrough is the result of a systematic approach linking molecular design principles with functional outcomes in azobenzene-DNA systems. By examining key structural features, such as nucleobase modifications, backbone